
News|Articles|June 6, 2005
New product newswire
From GlaxoSmithKline, Research Triangle Park, N.C., (919) 483-2100, comes Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed [Tdap]). The product is indicated as a booster vaccine to be given as a single dose to patients aged 10 to 18. This booster adds a pertussis component to the tetanus/diphtheria booster routinely administered to teens.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Overcoming the Structural Squeeze Through Policy and Coordination
2
Navigating Compounding Peptides and GLP-1s Through Regulations
3
How Rural Pharmacies Are Screening Thousands, Cutting Costs
4
Pharmacist Involvement Speeds Prior Authorization for GLP-1s
5


























